Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose chronic spontaneous urticaria (CSU) via ready-symptom recognition and evidence-based practices

Activity Description

In this activity, a panel of experts discusses overcoming diagnostic barriers in chronic spontaneous urticaria (CSU) through a discussion of the patient’s journey, delays in diagnosis, and review of guideline-recommended approaches to diagnosis and assessment of disease activity.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Autumn Burnette, MD, FACAAI
Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Jonathan A. Bernstein, MD, has financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Genentech, Ionis, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

Autumn Burnette, MD, FACAAI, has financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pharming, Pfizer, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, Astra Zeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose chronic spontaneous urticaria (CSU) via ready-symptom recognition and evidence-based practices

Activity Description

In this activity, a panel of experts discusses overcoming diagnostic barriers in chronic spontaneous urticaria (CSU) through a discussion of the patient’s journey, delays in diagnosis, and review of guideline-recommended approaches to diagnosis and assessment of disease activity.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Autumn Burnette, MD, FACAAI
Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Jonathan A. Bernstein, MD, has financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Genentech, Ionis, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

Autumn Burnette, MD, FACAAI, has financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pharming, Pfizer, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, Astra Zeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).

Learning Objectives

After completing this activity, the clinician should be able to:

• Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD) 
• Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD 
• Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD 

Activity Description

In this activity, a panel of interprofessional atopic dermatitis experts discuss challenging cases that have been submitted by physicians across the country. These atopic dermatitis cases will focus on evidence-based interprofessional management of patients with severe disease and comorbid asthma, including step care, misdiagnosis, and improving patient adherence.

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joy Logothetis, MMS, PA-C
Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant); AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly, Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos, YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM (an OTC product) (Other, Patent Pending).

Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).

Learning Objectives

After completing this activity, the clinician should be able to:

• Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD) 
• Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD 
• Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD 

Activity Description

In this activity, a panel of interprofessional atopic dermatitis experts discuss challenging cases that have been submitted by physicians across the country. These atopic dermatitis cases will focus on evidence-based interprofessional management of patients with severe disease and comorbid asthma, including step care, misdiagnosis, and improving patient adherence.

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joy Logothetis, MMS, PA-C
Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant); AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly, Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos, YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM (an OTC product) (Other, Patent Pending).

Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists and other health care professionals involved in the management of patients with atopic dermatitis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Identify patients with atopic dermatitis (AD) who may benefit from topical therapy.
• Examine the latest clinical evidence regarding emerging Janus kinase (JAK) inhibitors in late-stage development for the management of patients with AD.
• Assess how emerging JAK inhibitors could be included into existing treatment paradigms for adolescents and adults with AD.

Activity Description

Nearly 70% of patients with atopic dermatitis (AD) have mild disease, which in most cases can be managed in the primary care setting with basic skin care management and topical agents. Patients with moderate-to-severe AD are notoriously more difficult to treat. Until recently, systemic steroids were the only treatment option, and they have limited efficacy with a poor safety profile. Emerging options with novel mechanisms of action are showing promise in late-stage clinical trials. Janus kinase inhibition is being thoroughly investigated in both topical and oral deliveries. In this continuing education activity, expert clinicians discuss why newer therapies are needed for AD.

Activity Description

Introduction

Patient Selection and Standard of Care for Atopic Dermatitis
Eric L. Simpson, MD, MCR

Back to Basics: Mechanisms of Action of Therapies for Atopic Dermatitis
Amy S. Paller, MS, MD

Management of Atopic Dermatitis: Current and Emerging Therapies
Lawrence F. Eichenfield, MD

Panel Discussion

Conclusion

Activity Chair

Lawrence F. Eichenfield, MD
Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine
Rady Children’s Hospital San Diego
San Diego, CA

Disclosures:
Consulting Fee: AbbVie, Almirall, Arcutis Biotherapeutics, Arena, Dermavant, Dermira, Forte Biosciences, Galderma, Incyte, Lilly, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, Sanofi Genzyme
Contracted Research: AbbVie, Dermira, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi Genzyme, Valeant

Faculty

Amy S. Paller, MS, MD
Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL

Disclosures:
Consulting Fee: AbbVie, Arena, Bausch + Lomb, Bristol-Myers Squibb, Dermavant, Forte Biosciences, LEO Pharma, LifeMax, Lilly, Pfizer, Rapt, Regeneron, Sanofi
Contracted Research: AbbVie, Incyte, Janssen, Lilly, Regeneron, UCB

Eric L. Simpson, MD, MCR
Frances J. Storrs, M.D. Medical Dermatology Professor
Professor of Dermatology, School of Medicine
Director of Clinical Studies, Department of Dermatology
Oregon Health & Science University
Portland, OR

Disclosures:
Consulting Fee: AbbVie, Amgen, Arena, Benevolent AI, BiomX, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Evidera, Excerpta Medica, Forte Biosciences, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Medscape, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SPARC India
Contracted Research: AbbVie, Amgen, Incyte, Kyowa Kirin, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Tioga, Vanda

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Incyte Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists and other health care professionals involved in the management of patients with atopic dermatitis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Identify patients with atopic dermatitis (AD) who may benefit from topical therapy.
• Examine the latest clinical evidence regarding emerging Janus kinase (JAK) inhibitors in late-stage development for the management of patients with AD.
• Assess how emerging JAK inhibitors could be included into existing treatment paradigms for adolescents and adults with AD.

Activity Description

Nearly 70% of patients with atopic dermatitis (AD) have mild disease, which in most cases can be managed in the primary care setting with basic skin care management and topical agents. Patients with moderate-to-severe AD are notoriously more difficult to treat. Until recently, systemic steroids were the only treatment option, and they have limited efficacy with a poor safety profile. Emerging options with novel mechanisms of action are showing promise in late-stage clinical trials. Janus kinase inhibition is being thoroughly investigated in both topical and oral deliveries. In this continuing education activity, expert clinicians discuss why newer therapies are needed for AD.

Activity Description

Introduction

Patient Selection and Standard of Care for Atopic Dermatitis
Eric L. Simpson, MD, MCR

Back to Basics: Mechanisms of Action of Therapies for Atopic Dermatitis
Amy S. Paller, MS, MD

Management of Atopic Dermatitis: Current and Emerging Therapies
Lawrence F. Eichenfield, MD

Panel Discussion

Conclusion

Activity Chair

Lawrence F. Eichenfield, MD
Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine
Rady Children’s Hospital San Diego
San Diego, CA

Disclosures:
Consulting Fee: AbbVie, Almirall, Arcutis Biotherapeutics, Arena, Dermavant, Dermira, Forte Biosciences, Galderma, Incyte, Lilly, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, Sanofi Genzyme
Contracted Research: AbbVie, Dermira, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi Genzyme, Valeant

Faculty

Amy S. Paller, MS, MD
Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL

Disclosures:
Consulting Fee: AbbVie, Arena, Bausch + Lomb, Bristol-Myers Squibb, Dermavant, Forte Biosciences, LEO Pharma, LifeMax, Lilly, Pfizer, Rapt, Regeneron, Sanofi
Contracted Research: AbbVie, Incyte, Janssen, Lilly, Regeneron, UCB

Eric L. Simpson, MD, MCR
Frances J. Storrs, M.D. Medical Dermatology Professor
Professor of Dermatology, School of Medicine
Director of Clinical Studies, Department of Dermatology
Oregon Health & Science University
Portland, OR

Disclosures:
Consulting Fee: AbbVie, Amgen, Arena, Benevolent AI, BiomX, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Evidera, Excerpta Medica, Forte Biosciences, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Medscape, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SPARC India
Contracted Research: AbbVie, Amgen, Incyte, Kyowa Kirin, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Tioga, Vanda

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Incyte Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com